EPIX and Bracco settle Multihance patent feud:
This article was originally published in Clinica
Executive Summary
EPIX Medical and the Italian company Bracco have settled their legal dispute over EPIX's European patents on MRI contrast imaging agents. Cambridge, Massachusetts-based EPIX has granted Bracco a worldwide licence to the patents - owned by the Massachusetts General Hospital and exclusively licensed to EPIX - in return for a $10 million advance payment. Bracco has also agreed to withdraw its oppositions to the corresponding patent applications in Japan. The deal permits Bracco to market its Multihance MRI contrast agent for liver and central nervous system imaging in Europe and the US, though the product is awaiting US marketing clearance.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.